RespireRx's GABAkine Shows Preclinical Promise but Faces a $45M Capital Chasm and High Translational Risk

RespireRx Details Pipeline Progress and Funding Initiatives

RespireRx Pharmaceuticals Inc. has issued a progress report to its stakeholders, detailing significant scientific and preclinical development successes despite ongoing capital raising challenges. The company secured a $2.99 million NIH SBIR grant for its GABAkine epilepsy compound, KRM-II-81, and filed pre-applications for two Congressionally Directed Medical Research Programs (CDMRP) grants totaling approximately $14.6 million for its AMPAkine, CX1739, targeting central sleep apnea and spinal cord injury. RespireRx also signed an agreement to supply CX1739 for a $1.8 million DoD-funded spinal cord injury study. Concurrently, the company is pursuing a private placement offering of up to $45 million to address its capital needs and advance its diverse pipeline into early 2027.

• RespireRx has made substantial progress in securing non-dilutive funding, including an active $2,999,738 NIH SBIR award for KRM-II-81. Additionally, the company filed two significant CDMRP pre-applications for CX1739: one for approximately $9.8 million for a clinical trial in central sleep apnea in chronic opioid patients (filed July 15, 2026) and another for approximately $4.8 million for a clinical trial in spinal cord injury (filed August 3, 2026), demonstrating active pursuit of external funding for its pipeline.
• The company advanced its AMPAkine, CX1739, for spinal cord injury by signing a consulting and supply agreement with Shirley Ryan AbilityLab. This agreement facilitates a DoD-funded $1.8 million human clinical trial focused on improving bladder function in SCI patients. RespireRx will supply CX1739 and provide a right of reference to its IND, marking a crucial step towards clinical validation and potential therapeutic application in this area.
• RespireRx has achieved significant preclinical and financial milestones, including the successful scale-up of KRM-II-81, their GABAkine epilepsy compound, from milligram to kilogram quantities, with animal PK studies completed. Simultaneously, the company is actively engaged in a Rule 506(c) private placement offering, targeting up to $45 million across its entities (RespireRx, ResolutionRx Ltd, and EndeavourRx LLC) to secure necessary capital for ongoing research, development, and operational goals.

CX1739: Targeting Central Sleep Apnea and Other Indications

CX1739, a low-impact ampakine that selectively activates AMPA receptors without inducing excito-neurotoxicity, is being investigated beyond spinal cord injury for the emergency treatment of acute respiratory depression associated with drug abuse and overdose. Preclinical animal models have demonstrated that high-dose intravenous administration of CX1739 can rapidly reverse respiratory depression induced by the opioid agonist 030418, pentobarbital sodium, and ethanol. This therapeutic rationale is supported by the compound's favorable pharmacokinetic profile, notably its rapid blood-brain barrier penetration (Tmax = 2 minutes), which aligns with the requirement for a fast-acting reversal agent in overdose settings—a clinically significant unmet need given that approximately 69,000 opioid overdose deaths occur globally each year.

In addition to this indication, CX1739 has undergone a Phase 1 clinical study in healthy male volunteers designed to characterize its tolerability and pharmacokinetics, structured as a two-part trial. Part A employed a single ascending dose escalation design across doses ranging from 100–1200 mg in 48 participants, while Part B utilized a multiple ascending dose model with 300–600 mg administered twice daily for 7–10 days in 32 participants. CX1739 was well tolerated up to 900 mg once daily and 450 mg twice daily, with headache and nausea as the most frequently reported adverse effects. Pharmacokinetic analysis revealed a half-life of 6–9 hours, a Tmax of 1–5 hours, and dose-proportional Cmax and AUC values, findings that have supported progression toward Phase 2 clinical evaluation.

Beyond these clinical programs, preclinical exploration has extended to autism spectrum disorder, where CX1739 (alongside the related compound CX1837) was evaluated in adult male and female BTBR mice, a well-characterized model of autism-like behavior. Acute administration of both compounds, delivered via peanut butter pellets, reversed sociability deficits in BTBR mice, as measured by time spent sniffing a novel mouse versus a novel object—the most sensitive behavioral parameter in this model. It should be noted that some literature inputs pertain to CX-516, a structurally distinct ampakine, and to CX1837, a related but separate compound; these have been excluded from consideration here to maintain specificity to CX1739.

Addressing Unmet Needs in Spinal Cord Injury Treatment

Despite decades of research, spinal cord injury (SCI) treatment continues to face substantial obstacles spanning clinical trial design, healthcare system access, and long-term patient management. These challenges span from methodological hurdles in demonstrating clinically meaningful recovery to persistent gaps in specialized care delivery, particularly in resource-limited settings.

• Outcome measurement complexity: Demonstrating neurological improvement in SCI trials is insufficient on its own — any observed change must be shown to be clinically meaningful and impactful to the patient's daily life. This is further complicated by rehabilitation efforts, which aim to maximize function despite residual impairment, often masking small treatment-related gains, especially during the initial rehabilitation phase.

• High multimorbidity burden with low treatment rates: Community-dwelling individuals with SCI experience a median of 7 concurrent health conditions (IQR 4–9), most commonly spasticity, chronic pain, and sexual dysfunction. Despite this burden, treatment rates remain low (median 44%, IQR 25–64%), even for chronic or significant problems. Prevalence increases with age and is higher in non-traumatic versus traumatic SCI.

• Delayed and inequitable access to diagnostics in resource-limited settings: In Ghana, 23% of required CT scans were performed more than 48 hours after admission, and only 41% of patients could afford MRI. Pressure sores (23%) and pneumonia (21%) were the most common in-hospital complications, underscoring the need for improved rapid-response protocols at teaching hospitals.

• Limited generalizability of clinical research: Although registered clinical studies on acute SCI treatment have increased in number and diversity over the past two decades (116 studies identified from 2000–2020, predominantly interventional), most are single-institution efforts concentrated in North America (n=70), Europe (n=29), and Asia (n=15). Additionally, most studies impose an upper age limit, restricting age diversity and limiting applicability to older populations with SCI.

• Market and specialist care limitations: SCI's low incidence fails to generate sufficient demand to sustain specialized services in many regions. This is reflected in low rates of guideline-concordant urological care — for example, only 29% of veterans with supra-sacral SCI/D had urologist visits and 31% underwent cystometrography, despite 80% presenting with lower urinary tract symptoms within one year of injury.

• Shifting patient demographics straining care systems: Veteran populations with supra-sacral SCI/D show an aging trend, with mean age at diagnosis increasing by nearly 9 years from 2000 to 2023, alongside a sharp rise in diabetes prevalence (17% in 2000 to over 45% in 2022), compounding management complexity.

• Incomplete functional and vocational recovery: Only 71% of patients with isolated spinal injury had returned to work at 12 months, with 50% reporting workplace limitations and 37% not regaining pre-injury performance levels. Factors such as surgical treatment, female sex, and pre-injury workload (>30 h/week) were associated with lower odds of early return to work.

• Structural and social barriers in care delivery: In regions such as Tunisia, specialized rehabilitation facilities are critically scarce (available in only 13 of 24 governorates), compounded by a shortage of trained healthcare professionals, inconsistent application of disability rights, and social stigma — all of which hinder comprehensive access to care.